Los Angeles, January 22, 2020 -QY Research has made a new addition to its repository of pharma and healthcare market research reports. Bearing the title “Global Albumin (as Excipient) Market Research Report 2019,” the report sheds light on how the global market is expected to grow, and the factors that could support its growth in the near future. According to the forecasts presented in the report, the global albumin (as excipient) market is predicted to increase its value to over US$6.0 Bn by the end of 2025 while rising at a robust CAGR of 6.8% during the forecast period 2019-2025. In 2018, the global market value reached above US$4.0 Bn.
Get PDF sample copy of the report at: https://www.qyresearch.com/sample-form/form/1419835/global-albumin-as-excipient-market
Increasing Significance of Albumin in Tissue Engineering: Albumin is studied to help overcome challenges in the formulation of active pharmaceutical ingredients and offer certain advantages over other excipients. There are more factors that could help improve the global demand for albumin (as excipient). Some of them are provided below.
● Use of recombinant albumin as a blocking agent in ELISA applications
● Important role of albumin-based biomaterials in tissue engineering
● High demand for albumin-based drug delivery systems
● Application of albumin‐based hydrogels in cell transplantation
● Use of albumin in the coating of medical devices to improve their biocompatibility
Albumin as a Carrier for Cancer Therapies: Based on type, the global albumin (as excipient) market is segmented into recombinant albumin and human serum albumin. The authors of the report have also segmented the global albumin (as excipient) market into therapeutics, medical supplements, and cell culture media. In therapeutics, albumin is studied to show promise as a carrier for anti-cancer agents or cancer therapies. It is also used as a vital component of serum-free cell culture systems. Some studies show that egg albumin-based protein supplement may be effective in improving nutritional status in continuous ambulatory peritoneal dialysis patients.
North America as Region with High Market Attractiveness
Some of the positive factors working in the favor of the North America albumin (as excipient) market could be:
● High diabetes burden and increased chronic diabetes complications
● Strong advancement of the pharmaceutical and biotechnology industries
● Research on human serum albumin and its drug delivery applications
● Use of recombinant albumin in cell culture media applications
Meeting JP, EU, USP Specifications and Obtaining FDA, GHA Certifications: Some of the key manufacturers of albumin (as excipient) are CSL, HiMedia, Grifols, Ventria (InVitria), Takeda, Merck, Octapharma, Biotest, Hualan Bio, Albumedix, CBPO, Shanghai RAAS, LFB Group, and Kedrion. Leading companies competing in the global albumin (as excipient) market are anticipated to further improve their integrated safety systems, donor and donor selection screening, pharmacovigilance, virus removal and inactivation, plasma inventory and testing, and fractionation manufacturing facilities. They could also focus on obtaining Official Medicines Control Laboratory and other certifications and performing tri-testing to fulfill Pharmaceuticals and Medical Devices Agency (Japan), EMEA, FDA, and other requirements.
QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), expert’s resources (included energy automotive chemical medical ICT consumer goods etc.
QY Research, INC.
17890 Castleton, Suite 218,
Los Angeles, CA – 91748
USA: +1 626 428 8800
China: +86 1082 945 717
Japan: +81 9038 009 273
India: +91 9766 478 224
Emails – email@example.com